Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer

• Published in: Annals of oncology Vol. 22; no. 4; pp. 801 - 807
• Main Authors: Flanagan, J., Gray, P. Kathryn, Hahn, N., Hayes, J., Myers, L.J., Carney-Doebbeling, C., Sweeney, C.J.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01.04.2011; Oxford University Press
• Subjects: Aged; Aged, 80 and over; Androgen Antagonists - adverse effects; Androgen Antagonists - therapeutic use; Androgens; Antineoplastic agents; Biological and medical sciences; Gynecology. Andrology. Obstetrics; hormonal therapy; Humans; Kaplan-Meier Estimate; Male; Male genital diseases; Medical sciences; Metabolic diseases; metabolic syndrome; Metabolic Syndrome - chemically induced; Middle Aged; Miscellaneous; Nephrology. Urinary tract diseases; Orchiectomy; Other metabolic disorders; Pharmacology. Drug treatments; prostate cancer; Prostate-Specific Antigen - blood; Prostatic Neoplasms - blood; Prostatic Neoplasms - therapy; resistance; Retrospective Studies; Risk Factors; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; hormonal therapy; metabolic syndrome; prostate cancer; resistance; Endocrinopathy; Urinary system disease; Prostate disease; Hormone therapy; Metabolic diseases; Cardiovascular disease; Malignant tumor; Metabolic syndrome; Resistance; Castration; Male genital diseases; Prostate cancer; Cancer
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1093/annonc/mdq443

Metabolic syndrome (MS) is a set of risk factors that includes obesity and insulin resistance and has been implicated in the development of prostate cancer. Its impact on androgen deprivation therapy (ADT) efficacy has not been studied. Retrospective study of prostate cancer patients seen from 1998 to 2005 in a medical oncology clinic. MS, as defined by modified Adult Treatment Panel III criteria, was assessed at the time of initiation of ADT. The study end points were time to prostate-specific antigen (PSA) progression and overall survival (OS) from time of starting ADT. Eighty-two patients treated with ADT and data to assess for presence of MS were identified. Median age in men with and without MS was 70 years and 49% of the patients evaluated met criteria for MS. Median time to PSA progression for patients with MS was 16 versus 36 months without MS (P = 0.003). The median OS for patients with MS was 36.5 months after commencing ADT compared with 46.7 months for those patients without MS (P = 0.061). This preliminary data suggest that MS is a risk factor for earlier development of castration-resistant prostate cancer and support the need for a prospective evaluation of this finding.